Oxford BioDynamics (LON:OBD) Shares Down 22.4% – Should You Sell?

Oxford BioDynamics Plc (LON:OBD)’s stock price fell 22.4% during trading on Tuesday . The stock traded as low as GBX 0.36 ($0.00) and last traded at GBX 0.38 ($0.01). 75,864,211 shares were traded during trading, an increase of 172% from the average session volume of 27,912,859 shares. The stock had previously closed at GBX 0.48 ($0.01).

Oxford BioDynamics Price Performance

The company has a market capitalization of £7.45 million, a P/E ratio of -0.07 and a beta of 0.42. The firm’s fifty day moving average is GBX 0.42 and its 200 day moving average is GBX 0.45. The company has a debt-to-equity ratio of 370.22, a quick ratio of 2.80 and a current ratio of 0.68.

Oxford BioDynamics (LON:OBD) last issued its quarterly earnings results on Monday, June 30th. The biotechnology company reported GBX (0.70) (($0.01)) EPS for the quarter. Oxford BioDynamics had a negative net margin of 1,800.32% and a negative return on equity of 289.38%.

Oxford BioDynamics Company Profile

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.